Aprea Therapeutics, Inc. Common stock

APRENASDAQ • USD
0.41 USD
↘ 0.01 (2.45%)🟢LIVE (AS OF 12:48 PM EST)
🟢Market: OPEN

Aprea Therapeutics, Inc. Common stock (APRE) trades at $0.41 per share. Our models show a "Strong Sell" technical signal alongside a "Neutral" fundamental rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, APRE trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 13, 2026.

Open?$0.43
High?$0.44
Low?$0.40
Prev. Close?$0.42
Volume?78.7K
Avg. Volume?155.7K
VWAP?$0.42
Rel. Volume?0.51x
Bid / Ask
Bid?$0.35 × 100
Ask?$0.47 × 100
Spread?$0.12
Midpoint?$0.41
Valuation & Ratios
Market Cap?6.0M
Shares Out?14.2M
Float?10.6M
Float %?84.5%
P/E Ratio?N/A
P/B Ratio?0.17
EPS?-$1.00
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Employees
8
Market Cap
5.9M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2019-10-03
Address
3805 OLD EASTON ROAD
DOYLESTOWN, PA 18902
Phone: 215-948-4119
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
85
Piotroski F-Score?0/9Weak
Altman Z-Score?-11.79Distress
Confidence?43%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?4.94%Low
Short Interest?525.2K
Days to Cover?2.6
Free Float10.6M
Avg Daily Volume202.4K
Settlement Date2026-10-30
Financial Health
Current Ratio?9.67Strong
Quick Ratio?9.67Strong
Cash Ratio?9.52Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.17CHEAP▾
P/S?
Peers
100
S&P
3
1,786.12HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
2.1CHEAP▾
EV/Sales?
S&P
97
-9,555.31CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-41.5%WEAK▾
ROA?
S&P
3
-36.4%WEAK▾
Cash Flow & Enterprise
FCF?$-12739635
Enterprise Value?$-31886086
Fundamentals ratios updated end of day